The Debrief1d
The Promise and Peril of Gene Editing
In this installment, we delve into one of the most debated scientific advancements of our time: CRISPR gene-editing ...
CRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal year
CRISPR Therapeutics AG (NASDAQ:CRSP), a leading biotechnology company specializing in gene-based medicines with a market capitalization of $3.45 billion, stands at a critical juncture as it navigates ...
eLife3d
Crispant analysis in zebrafish as a tool for rapid functional screening of disease-causing genes for bone fragility
Crispant analysis in zebrafish serves as a powerful tool for the rapid functional screening of genes implicated in bone fragility disorders, like osteogenesis imperfecta and osteoporosis.
Gene editing extends lifespan in mouse model of prion disease
Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...
ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9
The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...